Drug Profile
ART I02
Alternative Names: AAV5.NF-kB.IFN-β; Recombinant AAV type2/5 containing a hIFN-b geneLatest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Arthrogen
- Developer MeiraGTx Netherlands
- Class Anti-inflammatories; Antirheumatics; Gene therapies
- Mechanism of Action Gene transference; Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for phase-I development in Rheumatic-disorders in Canada (Intra-articular, Injection)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Rheumatic-disorders in Netherlands (Intra-articular, Injection)
- 03 Jan 2018 Phase-I clinical trials in Rheumatic disorders in Canada (Intra-articular) (NCT03445715)